Comparison of NN5401 Versus Insulin Glargine, Both Combined With Metformin Treatment, in Subjects With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 530 participants.

Also called NCT01045707

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 530 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01045707
  • EudraCT 2009-011271-78
  • EudraCT 2009-015839-33
Other papers using this trial's data
  • Efficacy and Safety of Once-Daily Insulin Degludec/Insulin Aspart versus Insulin Glargine (U100) for 52 Weeks in Insulin-Naïve Patients with Type 2 Diabetes: A Randomized Controlled Trial PloS one, 2016 DOI, PubMed 27760129, PMC5070831 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Austria, India, Poland, Puerto Rico, Russia, South Korea, Spain, Türkiye (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01045707. Randomized; no masking; primary purpose treatment. Start 2010-01 (registry gives no type); primary completion 2010-10 (actual). Results posted on 2015-11-20.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Comparison of NN5401 Versus Insulin Glargine, Both Combined With Metformin Treatment, in Subjects With Type 2 Diabetes
Acronym
BOOST™
Condition
Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
insulin degludec/insulin aspart
Intervention (Drug)
insulin glargine
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct01045707
Content hash
bbe0fd2c02610e176972c2dd88c7f786e33afecb5609bc765c7dbf149a0c698e